Clinical trials: Castration Levels of Testosterone
Prostate Cancer
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response…
- Trial name
- NCT01420861
- Testing
- GTx-758
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GTx
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer
To evaluate whether the efficacy of the abiraterone acetate tablets (I) is comparable to that of the ZYTIGA®) by comparing the serum testosterone concentrations on Day 9 and/or Day 10 after oral administration of the two…
- Trial name
- NCT04862091
- Testing
- Abiraterone Acetate Tablets (I), ZYTIGA®
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer
Protocol G200712 is a Phase II, exploratory study to assess the effects of GTx-758 on serum prostate specific antigen (PSA) response ans serum PSA progression in men with Metastatic Castration Resistant Prostate Cancer (mCRPC) on…
- Trial name
- NCT01615120
- Testing
- GTx-758 125 mg, GTx-758 250 mg
- Where
- 26 sites in United States
- Volunteers
- 77 people
- Sponsor
- GTx